The C-Type Lectin of the Aggrecan G3 Domain Activates Complement

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Melin Fürst, Camilla ^a   Mörgelin, Matthias ^a   Vadstrup, Kasper ^b   Heinegård, Dick ^a   Aspberg, Anders ^b   Blom, Anna M ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; AGGRECAN G3; C TYPE LECTIN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT CONTROL PROTEIN; COMPLEMENT INHIBITOR; COMPLEMENT INHIBITOR FH; CORE PROTEIN; LECTIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; NORMAL HUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

AGGRECANS; ANIMALS; CARTILAGE; CATTLE; CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; HUMANS; MODELS, BIOLOGICAL; MUTATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS;

EID: 84876176589     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061407     Document Type: Article

References (44)

1. Ricklin D, Hajishengallis G, Yang K, Lambris JD, (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: 785-797.
2. Sjoberg AP, Trouw LA, Blom AM, (2009) Complement activation and inhibition: a delicate balance. Trends Immunol 30: 83-90.
3. Okroj M, Heinegard D, Holmdahl R, Blom AM, (2007) Rheumatoid arthritis and the complement system. Ann Med 39: 517-530.
4. Kojouharova M, Reid K, Gadjeva M, (2010) New insights into the molecular mechanisms of classical complement activation. Mol Immunol 47: 2154-2160.
5. Groeneveld TW, Oroszlan M, Owens RT, Faber-Krol MC, Bakker AC, et al. (2005) Interactions of the extracellular matrix proteoglycans decorin and biglycan with C1q and collectins. J Immunol 175: 4715-4723.
6. Sjoberg AP, Manderson GA, Morgelin M, Day AJ, Heinegard D, et al. (2009) Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol Immunol 46: 830-839.
7. Bing DH, Almeda S, Isliker H, Lahav J, Hynes RO, (1982) Fibronectin binds to the C1q component of complement. Proc Natl Acad Sci USA 79: 4198-4201.
8. Bohnsack JF, Tenner AJ, Laurie GW, Kleinman HK, Martin GR, et al. (1985) The C1q subunit of the first component of complement binds to laminin: a mechanism for the deposition and retention of immune complexes in basement membrane. Proc Natl Acad Sci USA 82: 3824-3828.
9. Sjoberg A, Onnerfjord P, Morgelin M, Heinegard D, Blom AM, (2005) The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem 280: 32301-32308.
10. Happonen KE, Saxne T, Aspberg A, Morgelin M, Heinegard D, et al. (2010) Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum 62: 3574-3583.
11. Happonen KE, Sjoberg AP, Morgelin M, Heinegard D, Blom AM, (2009) Complement inhibitor C4b-binding protein interacts directly with small glycoproteins of the extracellular matrix. J Immunol 182: 1518-1525.
12. Happonen KE, Saxne T, Geborek P, Andersson M, Bengtsson AA, et al. (2012) Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-alpha treatment. Arthritis research & therapy 14: R15.
13. Kiani C, Chen L, Wu YJ, Yee AJ, Yang BB, (2002) Structure and function of aggrecan. Cell Res 12: 19-32.
14. Aspberg A, (2012) The different roles of aggrecan interaction domains. J Histochem Cytochem 60: 987-996.
15. Heinegard D, (2009) Proteoglycans and more-from molecules to biology. Int J Exp Pathol 90: 575-586.
16. Aspberg A, Miura R, Bourdoulous S, Shimonaka M, Heinegard D, et al. (1997) The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein interactions independent of carbohydrate moiety. Proc Natl Acad Sci USA 94: 10116-10121.
17. Day JM, Olin AI, Murdoch AD, Canfield A, Sasaki T, et al. (2004) Alternative splicing in the aggrecan G3 domain influences binding interactions with tenascin-C and other extracellular matrix proteins. J Biol Chem 279: 12511-12518.
18. Aspberg A, Adam S, Kostka G, Timpl R, Heinegard D, (1999) Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican. J Biol Chem 274: 20444-20449.
19. Olin AI, Morgelin M, Sasaki T, Timpl R, Heinegard D, et al. (2001) The proteoglycans aggrecan and Versican form networks with fibulin-2 through their lectin domain binding. J Biol Chem 276: 1253-1261.
20. Isogai Z, Aspberg A, Keene DR, Ono RN, Reinhardt DP, et al. (2002) Versican interacts with fibrillin-1 and links extracellular microfibrils to other connective tissue networks. J Biol Chem 277: 4565-4572.
21. Vertel BM, Grier BL, Li H, Schwartz NB, (1994) The chondrodystrophy, nanomelia: biosynthesis and processing of the defective aggrecan precursor. Biochem J 301 (Pt 1): 211-216.
22. Stattin EL, Wiklund F, Lindblom K, Onnerfjord P, Jonsson BA, et al. (2010) A missense mutation in the aggrecan C-type lectin domain disrupts extracellular matrix interactions and causes dominant familial osteochondritis dissecans. Am J Hum Genet 86: 126-137.
23. Tompson SW, Merriman B, Funari VA, Fresquet M, Lachman RS, et al. (2009) A recessive skeletal dysplasia, SEMD aggrecan type, results from a missense mutation affecting the C-type lectin domain of aggrecan. Am J Hum Genet 84: 72-79.
24. Paulsson M, Morgelin M, Wiedemann H, Beardmore-Gray M, Dunham D, et al. (1987) Extended and globular protein domains in cartilage proteoglycans. Biochem J 245: 763-772.
25. Dudhia J, Davidson CM, Wells TM, Vynios DH, Hardingham TE, et al. (1996) Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage. Biochem J 313 (Pt 3): 933-940.
26. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, et al. (2011) Identification of a central role for complement in osteoarthritis. Nat Med 17: 1674-1679.
27. Heinegard D, Sommarin Y, (1987) Isolation and characterization of proteoglycans. Methods Enzymol 144: 319-372.
28. Tenner AJ, Lesavre PH, Cooper NR, (1981) Purification and radiolabeling of human C1q. J Immunol 127: 648-653.
29. Dahlback B, (1983) Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S. Biochem J. 209: 847-856.
30. Blom AM, Kask L, Dahlback B, (2003) CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b. Mol Immunol 39: 547-556.
31. Hein E, Honore C, Skjoedt MO, Munthe-Fog L, Hummelshoj T, et al. (2010) Functional analysis of Ficolin-3 mediated complement activation. PLoS One 5: e15443.
32. Munthe-Fog L, Hummelshoj T, Hansen BE, Koch C, Madsen HO, et al. (2007) The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. Scand J Immunol 65: 383-392.
33. Munthe-Fog L, Hummelshoj T, Ma YJ, Hansen BE, Koch C, et al. (2008) Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state. Mol Immunol 45: 2660-2666.
34. Engel J, Furthmayr H, (1987) Electron microscopy and other physical methods for the characterization of extracellular matrix components: laminin, fibronectin, collagen IV, collagen VI, and proteoglycans. Methods Enzymol 145: 3-78.
35. Lundell A, Olin AI, Morgelin M, al-Karadaghi S, Aspberg A, et al. (2004) Structural basis for interactions between tenascins and lectican C-type lectin domains: evidence for a crosslinking role for tenascins. Structure 12: 1495-1506.
36. Ferreira VP, Cortes C, Pangburn MK, (2010) Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement. Immunobiology 215: 932-940.
37. Happonen KE, Sjoberg AP, Morgelin M, Heinegard D, Blom AM, (2009) Complement inhibitor C4b-binding protein interacts directly with small glycoproteins of the extracellular matrix. J Immunol 182: 1518-1525.
38. Wang Y, Rollins SA, Madri JA, Matis LA, (1995) Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci U S A 92: 8955-8959.
39. Song H, Qiao F, Atkinson C, Holers VM, Tomlinson S, (2007) A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol 179: 7860-7867.
40. Sjoberg AP, Trouw LA, Clark SJ, Sjolander J, Heinegard D, et al. (2007) The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J Biol Chem 282: 10894-10900.
41. Sjolander J, Westermark GT, Renstrom E, Blom AM, (2012) Islet Amyloid Polypeptide Triggers Limited Complement Activation and Binds Complement Inhibitor C4b-binding Protein, Which Enhances Fibril Formation. J Biol Chem 287: 10824-10833.
42. Sjoberg AP, Nystrom S, Hammarstrom P, Blom AM, (2008) Native, amyloid fibrils and beta-oligomers of the C-terminal domain of human prion protein display differential activation of complement and bind C1q, factor H and C4b-binding protein directly. Mol Immunol 45: 3213-3221.
43. Trouw LA, Bengtsson AA, Gelderman KA, Dahlback B, Sturfelt G, et al. (2007) C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J Biol Chem 282: 28540-28548.
44. Happonen KE, Heinegard D, Saxne T, Blom AM, (2012) Interactions of the complement system with molecules of extracellular matrix: relevance for joint diseases. Immunobiology 217: 1088-1096.